Repositioning Candidate Details
| Candidate ID: | R0517 |
| Source ID: | DB12236 |
| Source Type: | investigational |
| Compound Type: | small molecule |
| Compound Name: | Bexagliflozin |
| Synonyms: | |
| Molecular Formula: | C24H29ClO7 |
| SMILES: | OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)C1=CC=C(Cl)C(CC2=CC=C(OCCOC3CC3)C=C2)=C1 |
| Structure: |
|
| DrugBank Description: | Bexagliflozin is under investigation for the treatment of Type 2 Diabetes Mellitus. Bexagliflozin has been investigated for the treatment of Diabetes Mellitus and Type2 Diabetes Mellitus. |
| CAS Number: | 1118567-05-7 |
| Molecular Weight: | 464.94 |
| DrugBank Indication: | |
| DrugBank Pharmacology: | |
| DrugBank MoA: | |
| Targets: | Sodium/glucose cotransporter 2 |
| Inclusion Criteria: |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Diseases ID | DO ID | Disease Name | Definition | Class |
|---|